TRIMTECH extends its seed round to $47M for developing protein degradation drugs, led by Johnson & Johnson Innovation and BGF.
PRIVATEJun 23, 2026
Amount Raised
$47 Million
Round Type
Seed
CambridgeBiotechnologyHealth CareTherapeutics
Investors
Pfizer VenturesCambridge Innovation CapitalDementia Discovery FundM VenturesStart CodonCambridge Enterprise VenturesMP Healthcare Venture ManagementEli Lilly And CompanyJohnson & Johnson InnovationBgf
Description
TRIMTECH, a biotech from Cambridge, has extended its seed round to $47M for its work on small molecule drugs targeting toxic protein aggregates related to neurodegenerative diseases. This round was led by Johnson & Johnson Innovation and BGF, joining several existing investors. The funding will support the development of their TRIMTAC and TRIMGLUE platforms aimed at selectively degrading harmful protein aggregates while preserving functional forms. CEO Nicola Thompson highlighted the funding's role in advancing their portfolio of CNS penetrant degraders.
Who to call at TRIMTECH Therapeutics, and when
A new round usually means TRIMTECH Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day TRIMTECH Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TRIMTECH Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TRIMTECH Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
TRIMTECH Therapeutics
Location
Cambridge, England, United Kingdom
About
TRIMTECH Therapeutics is a biotech company focused on harnessing targeted protein degradation for the treatment of neurodegenerative diseases. The company has developed a pipeline of CNS-penetrant therapeutics based on their unique degrader molecules known as TRIMTACs. By leveraging the properties of the E3 ubiquitin ligase TRIM21, TRIMTECH aims to address significant treatment gaps for conditions like Alzheimer's and Huntington's disease. Founded by prominent organizations and experts, TRIMTECH is committed to advancing innovative therapies for complex diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TRIMTECH Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeutics